Connection

MEENAKSHI HEGDE to T-Lymphocytes

This is a "connection" page, showing publications MEENAKSHI HEGDE has written about T-Lymphocytes.
Connection Strength

2.147
  1. A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer Res Commun. 2025 Mar 01; 5(3):527-548.
    View in: PubMed
    Score: 0.523
  2. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549.
    View in: PubMed
    Score: 0.380
  3. Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
    View in: PubMed
    Score: 0.288
  4. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101.
    View in: PubMed
    Score: 0.235
  5. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 06; 5(6):880-894.
    View in: PubMed
    Score: 0.123
  6. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia. 2021 01; 35(1):75-89.
    View in: PubMed
    Score: 0.093
  7. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2018 03 27; 20(4):506-518.
    View in: PubMed
    Score: 0.081
  8. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
    View in: PubMed
    Score: 0.079
  9. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.
    View in: PubMed
    Score: 0.077
  10. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
    View in: PubMed
    Score: 0.066
  11. T cells redirected to interleukin-13Ra2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Ra1. Cytotherapy. 2014 Aug; 16(8):1121-31.
    View in: PubMed
    Score: 0.062
  12. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.053
  13. Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
    View in: PubMed
    Score: 0.032
  14. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. Cytotherapy. 2024 Sep; 26(9):1026-1032.
    View in: PubMed
    Score: 0.031
  15. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020 05; 26(5):720-731.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.